Posted On: 07/13/2014 5:12:48 PM
Post# of 30066
Either the market (discount future revenue) decides the stock price which is not within Gerald's control, or buyout to provide more deteministic market valuation and hence stock price.
Lympro deals may be structured with a hybrid of partnership(s) and full regional or application rights buyout(s), e.g.
US: partnership with a pharma, or full rights buyout for CTE+TBI
Europe: full rights buyout by same or different pharma, e.g. $800m (which likely levels AMBS market cap up by additional $800m)
China: full rights buyout, e.g. $600m (additional $600m market cap)
The confidence of Gerald in stating possibility of no RS on several occasions may stem from possible financial engineering approach to deals.
Lympro deals may be structured with a hybrid of partnership(s) and full regional or application rights buyout(s), e.g.
US: partnership with a pharma, or full rights buyout for CTE+TBI
Europe: full rights buyout by same or different pharma, e.g. $800m (which likely levels AMBS market cap up by additional $800m)
China: full rights buyout, e.g. $600m (additional $600m market cap)
The confidence of Gerald in stating possibility of no RS on several occasions may stem from possible financial engineering approach to deals.
(0)
(0)
